MedTrace Logo

SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs

NCT06522048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-07-29

No results posted yet for this study

Summary

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment. With the increasing use of immune checkpoint inhibitors (ICIs) in oncology, it is crucial to understand the differences in SJS/TEN induced by ICIs compared to other drugs. This study aims to compare the clinical manifestations and outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) or other severity of cutaneous adverse events induced by immune checkpoint inhibitors (ICIs), versus other types of drugs. We analyzed differences in clinical characteristics, treatment methods, outcomes, and survival time and quality of life.

Conditions

  • Immune Checkpoint Inhibitor-Induced Dermatitis
  • Stevens-Johnson Syndrome, Drug-Induced
  • Toxic Epidermal Necrolysis Due to Drug

Interventions

OTHER

Observational studies do not require intervention

This is an observational retrospective study and does not require any intervention.

Sponsors & Collaborators

  • Chao Ji

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06522048 on ClinicalTrials.gov